China Medical System’s Innovative Oral Drug for Vitiligo, Povorcitinib Enrolls First Patient in China Phase III Clinical Trial

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”, 867.HK/8A8.SG) is pleased to announce that its subsidiary,...